Survival after second-line therapy in patients with metastatic kidney cancer treated with first-line immunotherapy combinations
This study looked at real world information from patients with [...]
Ipilimumab-nivolumab and axitinib-pembrolizumab combinations produce similar survival times
When ipilimumab plus nivolumab or axitinib plus pembrolizumab are used [...]
Nivolumab compared to cabozantinib as a second- or third-line treatment
This study looked at real world data from people with [...]
Kidney cancer patient summit on immunotherapy/TKI combinations
The following presentations from the Educated Patient® Kidney Cancer Summit [...]
Biomarker for predicting disease recurrence in non-metastatic papillary kidney cancer
A biomarker is a biological molecule found in blood, other [...]
Outcomes of patients who stopped immunotherapy due to immune-related side effects
Immunotherapy has changed the way advanced renal cell carcinoma (RCC) [...]
Atezolizumab plus bevacizumab does not improve survival in kidney cancer
Results from the IMmotion151 phase III clinical trial were published [...]
First-line nivolumab plus ipilimumab in kidney cancer patients without nephrectomy
A recent post hoc analysis of the CheckMate 214 trial [...]
Cabozantinib for the treatment of kidney cancer brain metastases
Brain metastases resulting from the spread of renal cell carcinoma [...]
Survival after nephrectomy for various kidney cancer subtypes
Data presented at the American Urological Association (AUA) 2021 meeting [...]
